BOSTON & SAN FRANCISCO –The USD 200 million third and largest fund of Vertex Ventures HC (VVHC), a women-led global healthcare investment organization, has just begun operations. Fund III will assist and empower ground-breaking life sciences and medical technology firms to foster innovation and enhance patient outcomes.
According to Lori Hu, Managing Director, San Francisco, “As technology continues to reshape industries and science continues to advance, VVHC recognizes the tremendous potential of companies that hold promise for transforming healthcare and driving societal impact.” “As one of the few women-led funds in the healthcare sector, we are proud of our track record of success supporting visionary entrepreneurs from company formation through exit.”
Managing Directors Lori Hu and Christine Brennan is in charge of VVHC, which is supported by a diversified investment strategy that prioritizes science. They have extensive operational and investing expertise, individually and collectively, having managed multiple investments in businesses that have exited mergers and acquisitions (M&A) or initial public offers (IPO). In order to build teams that are well-positioned for success and to improve diversity at the board and C-suite, VVHC places a strong emphasis on the long term.
According to Christine Brennan, Ph.D., Managing Director, Boston, “With our third fund, we will continue to fuel the growth and advancement of medicines by providing capital, strategic advice, and invaluable expertise to companies developing cutting-edge solutions and to weather the ups and downs of market cycles.”
To produce novel medications for patients, VVHC Fund III will look for investment opportunities in early-stage businesses that exhibit disruptive technology, ground-breaking research, and a clear roadmap. Access to essential resources, strategic alliances, and mentorship will be made possible by the vast network of business leaders, entrepreneurs, and researchers who make up VVHC.
Lori Hu, a member of the VVHC founding team, and Christine Brennan, Ph.D., who joined VVHC in 2022 after holding positions at MRL Ventures Fund and Novartis Venture Fund, will lead Fund III. As the former CEO of Ivantis, which Alcon bought, David Van Metre joined this year as a Venture Partner and provided a wealth of operational expertise in medical technologies. Additionally, business development and functional experts Faheem Hasnain and George Golumbeski, Ph.D. veterans of the industry, continue to serve as Venture Advisors.
We try our best to fact-check and bring the best, well-researched, and non-plagiarized content to you. Please let us know
-if there are any discrepancies in any of our published stories,
-how we can improve,
-what stories you would like us to cover and what information you are looking for, in the comments section below or through our contact form! We look forward to your feedback, and thank you for stopping by!
Next Article
, a women-led global healthcare investment organization, has just begun operations. Fund III will assist and empower ground-breaking life sciences and medical technology firms to foster innovation and enhance patient outcomes.){kind=link}